ReviewVaccines2015
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.
Review in Vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 114 citations in OpenAlex.
- SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine.Applied microbiology and biotechnology · 2026Article
- Bioengineering modification and application of bacterial outer membrane vesicles.International journal of medical sciences · 2026Review
- Next-generation mRNA vaccines eliciting robust protection against multidrug-resistant Enterobacteriaceae.NPJ vaccines · 2025Article
- Article
- Article
- Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria.Materials today. Bio · 2024Review
- Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19.Microbial cell factories · 2024Article
- Transformed Salmonella typhimurium SL7207/pcDNA-CCOL2A1 as an orally administered DNA vaccine.AMB Express · 2024Article
- Bacteria-Based Nanoprobes for Cancer Therapy.International journal of nanomedicine · 2024Review
- RNA Vaccines: Yeast as a Novel Antigen Vehicle.Vaccines · 2023Review
- Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer.Pharmaceutics · 2023Review
- Engineering a dual vaccine against COVID-19 and tuberculosis.Frontiers in cellular and infection microbiology · 2023Article
- Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution.Vaccines · 2022Review
- A SARS-CoV-2 oral vaccine development strategy based on the attenuated Salmonella type III secretion system.Journal of applied microbiology · 2022Article
- Article
- Live-Attenuated Oral Vaccines to ReduceVaccines · 2022Article
- An Engineered Outer Membrane-DefectiveJournal of microbiology and biotechnology · 2022Article
- Review
- COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.Journal of microbiology (Seoul, Korea) · 2022Review
- Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response.Global challenges (Hoboken, NJ) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically attenuated microorganisms, including pathogenic and commensal bacteria, can be engineered to carry and deliver heterologous antigens to elicit host immunity against both the vector as well as the pathogen from which the donor gene is derived. These live attenuated bacterial vectors have been given much attention due to their capacity to induce a broad range of immune responses including localized mucosal, as well as systemic humoral and/or cell-mediated immunity. In addition, the unique tumor-homing characteristics of these bacterial vectors has also been exploited for alternative anti-tumor vaccines and therapies. In such approach, tumor-associated antigen, immunostimulatory molecules, anti-tumor drugs, or nucleotides (DNA or RNA) are delivered. Different potential vectors are appropriate for specific applications, depending on their pathogenic routes. In this review, we survey and summarize the main features of the different types of live bacterial vectors and discussed the clinical applications in the field of vaccinology. In addition, different approaches for using live attenuated bacterial vectors for anti-cancer therapy is discussed, and some promising pre-clinical and clinical studies in this field are outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.